Okuda Hirofumi, Sugiura Hideshi, Yamada Kenji, Hayashi Norio, Soga Norihito, Ogura Yuji
Dept. of Orthopedic, Aichi Cancer Center Hospital.
Gan To Kagaku Ryoho. 2013 Nov;40(11):1497-501.
Bone metastases from renal cell carcinoma(RCC)are almost osteolytic and often cause pathological fractures. The objective of this study was to assess the efficacy of radiotherapy and zoledronic acid in patients with bone metastases from RCC.
We retrospectively analyzed 12 patients with bone metastases from RCC. Of these patients, 5 were treated with radiotherapy(RT group)and 7 were treated with a combination of radiotherapy and zoledronic acid(RT+Z group). We analyzed the radiological changes in the bone metastases and evaluated the response rate, survival rate, and skeletal-related event(SRE)rate.
Radiologically, 2 patients showed progressive disease(PD), 3 showed stable disease( SD), 1 showed partial response(PR), and 1 showed complete response(CR)in the RT group(response rate: 28.6%). In the RT+Z group, 1 patient showed PD, 3 showed PR, and 1 showed CR(response rate: 80.0%).
With regard to radiological changes, the response rate was higher in the RT group than in the RT+Z group, but the survival rate did not differ significantly between the 2 groups. SREs were less frequent in the RT+Z group than in the RT group.
肾细胞癌（RCC）骨转移几乎均为溶骨性，且常导致病理性骨折。本研究的目的是评估放疗和唑来膦酸对RCC骨转移患者的疗效。
我们回顾性分析了12例RCC骨转移患者。其中，5例接受放疗（放疗组），7例接受放疗联合唑来膦酸治疗（放疗+唑来膦酸组）。我们分析了骨转移的影像学变化，并评估缓解率、生存率和骨相关事件（SRE）发生率。
影像学方面，放疗组2例患者疾病进展（PD），3例病情稳定（SD），1例部分缓解（PR），1例完全缓解（CR）（缓解率：28.6%）。放疗+唑来膦酸组，1例患者疾病进展，3例部分缓解，1例完全缓解（缓解率：80.0%）。
关于影像学变化，放疗组的缓解率高于放疗+唑来膦酸组，但两组生存率无显著差异。放疗+唑来膦酸组的SREs发生率低于放疗组。
